CombiGene Valuation

Is COMBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COMBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate COMBI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate COMBI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COMBI?

Key metric: As COMBI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for COMBI. This is calculated by dividing COMBI's market cap by their current revenue.
What is COMBI's PS Ratio?
PS Ratio	16.1x
Sales	SEK 3.15m
Market Cap	SEK 50.69m

COMBI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does COMBI's PS Ratio compare to its peers?

The above table shows the PS ratio for COMBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	10.3x
LIDDS LIDDS	17.3x	n/a	SEK 16.3m
QUIA Quia Pharma	9.7x	n/a	SEK 48.4m
EXPRS2 ExpreS2ion Biotech Holding	5.1x	0.3%	SEK 40.4m
NICA Nanologica	9.2x	95.5%	SEK 80.4m
COMBI CombiGene	16.1x	n/a	SEK 50.7m

Price-To-Sales vs Peers: COMBI is expensive based on its Price-To-Sales Ratio (16.1x) compared to the peer average (10.3x).

Price to Sales Ratio vs Industry

How does COMBI's PS Ratio compare vs other companies in the SE Biotechs Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
XBRANE Xbrane Biopharma	1.5x	61.1%	US$26.67m
SPRINT Sprint Bioscience	1.8x	27.6%	US$9.89m
PMDS PMD Device Solutions	0.9x	62.0%	US$3.19m
GEAN Genetic Analysis	1.1x	n/a	US$1.96m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: COMBI is expensive based on its Price-To-Sales Ratio (16.1x) compared to the Swedish Biotechs industry average (12.2x).

Price to Sales Ratio vs Fair Ratio

What is COMBI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COMBI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	16.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate COMBI's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

5.0%

8.2%

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

-2.7%

14.5%

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

-8.1%

n/a